August 21, 2025
Kite, a Gilead company, unveiled a definitive agreement to acquire Philadelphia-based Interius BioTherapeutics—a privately held biotech innovator developing in vivo CAR T-cell therapies—for $350 million in cash.This marks Kite’s second acquisition of a Philadelphia-based company, following the previous deal for TMunity. This is another signal for the local biotech ecosystem that reinforces its leadership as an innovator in the broader cell therapy sector that had previously earned the region the moniker of “Cellicon Valley”.
Interius’s in vivo platform represents a significant departure from traditional CAR T-cell therapies, which require the laborious processes of harvesting, engineering, and reinfusion. Instead, Interius offers a streamlined, off-the-shelf but personalized therapy that generates CAR T-cells directly in the patient’s body via a single intravenous infusion—eliminating the need for preconditioning chemotherapy.
As Cindy Perettie, Kite’s Executive Vice President, aptly put it: “In vivo therapy is a promising frontier with the potential to transform how we approach treating patients, shifting to more accessible and scalable solutions.”
This technology promises to redefine the next era of cell therapy. It hints at a future where gene-editing and therapeutic cell generation may occur within living patients, reducing both cost barriers and procedural complexity.
Philadelphia’s Growing Role as a Therapeutic Hub
Philadelphia’s significance in this story goes beyond geography. Interius, based in Philly, joins TMunity in forming a growing pipeline of locally based acquisitions by Kite. With the integration of Interius’s team and labs into Kite’s operations, the company plans to establish a center of excellence in Philadelphia, designed to accelerate development of next‑generation in vivo therapies.
This move consolidates Philadelphia’s evolving reputation as a magnet for advanced therapeutics innovation, deepening ties between academia, startups, and established biopharma. For professionals and executives in the Greater Philadelphia region—including investors, industry leaders, and emerging entrepreneurs—it signals continued momentum and opportunity.
One of Kite’s largest operations is in Frederick, Maryland, just a two hour drive from Philly which has helped to position the State as a dominant hub for CAR T manufacturing. One can easily see a “Car-T corridor” developing between Philadelphia’s proven research ecosystem and the regulatory and manufacturing center of excellence that is growing in Maryland.
Elevating Kite’s Capabilities—and Access
Pre‑existing strengths serve as the foundation of this deal. Kite already boasts the largest in‑house cell therapy manufacturing footprint in the world, with capabilities spanning process development to commercial production. By absorbing Interius’s modular, scalable platform, Kite can now offer therapies that are both more patient-friendly and adaptable across disease states.
Phil Johnson, President and CEO of Interius, underscored the impact: “This marks a pivotal step … with the addition of Kite’s deep expertise and global infrastructure, we’re well‑positioned to move quickly into multiple therapeutic areas, expand access to cell therapies and deliver meaningful innovation to patients.”
This integration could democratize CAR T therapies, particularly for patients with aggressive or rapidly advancing disease, by reducing delays and scaling treatment access—an important advance for healthcare professionals and institutions in Maryland and beyond.
Kite is paying $350 million in cash, subject to customary adjustments, and anticipates that the acquisition will reduce Gilead’s 2025 EPS by roughly $0.23–$0.25 on both GAAP and non‑GAAP bases. Although modest from a corporate finance lens, this reflects Kite’s strategic prioritization of long-term innovation over short-term earnings preservation.
Regulatory approval remains a gating factor—the transaction hinges on clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other conditions. Advisors to the deal are TD Cowen for Kite and Evercore for Interius.
In capturing Interius, Kite is not merely acquiring a platform—it is consolidating a vision: of CAR T therapies reimagined, of innovation ventured not only in specialized labs but delivered directly to patients’ bodies, and of regional biotech ecosystems elevated into global relevance.
For industry executives, academic leaders, and practitioners in both states, the message is clear: the future of therapy is landing in your backyard.
